1 / 14

Funding for Haemophilia Care in Europe: A Taste of Things to Come

mliss
Download Presentation

Funding for Haemophilia Care in Europe: A Taste of Things to Come

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. Funding for Haemophilia Care in Europe: A Taste of Things to Come? Adam Hutchings GMAS LLP WFH 24 September 2009

    3. Haemophilia care has not been a primary target for cost savings Funding has often been provided direct to HTC’s from central government/sick funds No Health Technology Assessment of haemophilia treatment approaches to date Most new products launched in the last 10 years, all are available for use in nearly every market. (Anecdotally) most patients who need it are receiving orthopaedic surgery – including patients with FVIII inhibitors

    7. Economics of haemophilia are not unambiguous

    8. Perception of unmet need in haemophilia is diminishing? Multiple effective treatments available Product safety has progressed dramatically Life expectancy is rising Patient quality of life is close to population norms Patients are starting to develop conditions of elderly (e.g osteoporosis) Knowledge of disease history is lower in younger payers

    9. Health Technology Assessment

    10. Capped haemophilia budgets

    11. National factor tenders

    13. Establish relationships with policy makers and payers Educate them about haemophilia Early warning about impending action Allows opportunity to sculpt the nature/scope of any review Proactively develop local guidelines German example: annual haemophilia roundtable with G-BA, patient representatives, physicians and industry

    14. Data is key to defending treatment levels: Clinical Economic Quality of life ‘Experiential’ These can be collected through Patient records Registries Clinical trials Patient surveys Patients need to understand that the quality of their future care is dependent upon their participation in data collection programs

More Related